|
1
|
Zhang X, Harmsen WS, Mettler TA, Kim WR,
Roberts RO, Therneau TM, Roberts LR and Chaiteerakij R:
Continuation of metformin use after a diagnosis of cirrhosis
significantly improves survival of patients with diabetes.
Hepatology. 60:2008–2016. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Day CP and James OF: Steatohepatitis: A
tale of two ‘hits’? Gastroenterology. 114:842–845. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Anstee QM, Daly AK and Day CP: Genetics of
alcoholic and nonalcoholic fatty liver disease. Semin Liver Dis.
31:128–146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lake AD, Novak P, Hardwick RN,
Flores-Keown B, Zhao F, Klimecki WT and Cherrington NJ: The
adaptive endoplasmic reticulum stress response to lipotoxicity in
progressive human nonalcoholic fatty liver disease. Toxicol Sci.
137:26–35. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Anderson N and Borlak J: Molecular
mechanisms and therapeutic targets in steatosis and
steatohepatitis. Pharmacol Rev. 60:311–357. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Naik A, Belič A, Zanger UM and Rozman D:
Molecular interactions between NAFLD and xenobiotic metabolism.
Front Genet. 4:22013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang D, Liu ZX, Choi CS, Tian L, Kibbey
R, Dong J, Cline GW, Wood PA and Shulman GI: Mitochondrial
dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency
causes hepatic steatosis and hepatic insulin resistance. Proc Natl
Acad Sci USA. 104:17075–17080. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Duvnjak M, Lerotić I, Barsić N, Tomasić V,
Jukić L Virović and Velagić V: Pathogenesis and management issues
for non-alcoholic fatty liver disease. World J Gastroenterol.
13:4539–4550. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bradbury MW and Berk PD: Lipid metabolism
in hepatic steatosis. Clin Liver Dis. 8639–671. (xi)2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
de Almeida IT, Cortez-Pinto H, Fidalgo G,
Rodrigues D and Camilo ME: Plasma total and free fatty acids
composition in human non-alcoholic steatohepatitis. Clin Nutr.
21:219–223. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Malaguarnera L, Di Rosa M, Zambito AM,
dell'Ombra N, Nicoletti F and Malaguarnera M: Chitotriosidase gene
expression in Kupffer cells from patients with non-alcoholic fatty
liver disease. Gut. 55:1313–1320. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kadowaki T, Yamauchi T, Kubota N, Hara K,
Ueki K and Tobe K: Adiponectin and adiponectin receptors in insulin
resistance, diabetes, and the metabolic syndrome. J Clin Invest.
116:1784–1792. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Müssig K, Heni M, Thamer C, Kantartzis K,
Machicao F, Stefan N, Fritsche A, Häring HU and Staiger H: The
ENPP1 K121Q polymorphism determines individual susceptibility to
the insulin-sensitising effect of lifestyle intervention.
Diabetologia. 53:504–509. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dongiovanni P, Valenti L, Rametta R, Daly
AK, Nobili V, Mozzi E, Leathart JB, Pietrobattista A, Burt AD,
Maggioni M, et al: Genetic variants regulating insulin receptor
signalling are associated with the severity of liver damage in
patients with non-alcoholic fatty liver disease. Gut. 59:267–273.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Parola M and Marra F: Adipokines and redox
signaling: Impact on fatty liver disease. Antioxid Redox Signal.
15:461–483. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tokushige K, Hashimoto E, Noto H, Yatsuji
S, Taniai M, Torii N and Shiratori K: Influence of adiponectin gene
polymorphisms in Japanese patients with non-alcoholic fatty liver
disease. J Gastroenterol. 44:976–982. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wong VW, Wong GL, Tsang SW, Hui AY, Chan
AW, Choi PC, So WY, Tse AM, Chan FK, Sung JJ, et al: Genetic
polymorphisms of adiponectin and tumor necrosis factor-alpha and
nonalcoholic fatty liver disease in Chinese people. J Gastroenterol
Hepatol. 23:914–921. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang BF, Wang Y, Ao R, Tong J and Wang BY:
AdipoQ T45 G and G276 T polymorphisms and susceptibility to
nonalcoholic fatty liver disease among Asian populations: A
meta-analysis and meta-regression. J Clin Lab Anal. 30:47–57. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hashemi M, Bojd H Hanafi, Nasab E
Eskandari, Bahari A, Hashemzehi NA, Shafieipour S, Narouie B,
Taheri M and Ghavami S: Association of adiponectin rs1501299 and
rs266729 gene polymorphisms with nonalcoholic fatty liver disease.
Hepat Mon. 13:e95272013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Muse ED, Obici S, Bhanot S, Monia BP,
McKay RA, Rajala MW, Scherer PE and Rossetti L: Role of resistin in
diet-induced hepatic insulin resistance. J Clin Invest.
114:232–239. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Singhal NS, Patel RT, Qi Y, Lee YS and
Ahima RS: Loss of resistin ameliorates hyperlipidemia and hepatic
steatosis in leptin-deficient mice. Am J Physiol Endocrinol Metab.
295:E331–E338. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tomaru T, Steger DJ, Lefterova MI, Schupp
M and Lazar MA: Adipocyte-specific expression of murine resistin is
mediated by synergism between peroxisome proliferator-activated
receptor gamma and CCAAT/enhancer-binding proteins. J Biol Chem.
284:6116–6125. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kumar S, Gupta V, Srivastava N, Gupta V,
Mishra S, Mishra S, Shankar M Natu, Roy U, Chandra A, Negi MP, et
al: Resistin 420C/G gene polymorphism on circulating resistin,
metabolic risk factors and insulin resistance in adult women.
Immunol Lett. 162(2 Pt B): 287–291. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang LY, Jin YJ, Jin QS, Lin LY, Zhang DD
and Kong LL: Association between resistin +299A/A genotype and
nonalcoholic fatty liver disease in Chinese patients with type 2
diabetes mellitus. Gene. 529:340–344. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
El-Shal AS, Pasha HF and Rashad NM:
Association of resistin gene polymorphisms with insulin resistance
in Egyptian obese patients. Gene. 515:233–238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu H, Sun J, Sun L, Shu X, Xu Y and Xie D:
Polymorphism of human leptin receptor gene is associated with type
2 diabetic patients complicated with non-alcoholic fatty liver
disease in China. J Gastroenterol Hepatol. 24:228–232. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Swellam M and Hamdy N: Association of
nonalcoholic fatty liver disease with a single nucleotide
polymorphism on the gene encoding leptin receptor. IUBMB Life.
64:180–186. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zain SM, Mohamed Z, Mahadeva S, Cheah PL,
Rampal S, Chin KF, Mahfudz AS, Basu RC, Tan HL and Mohamed R:
Impact of leptin receptor gene variants on risk of non-alcoholic
fatty liver disease and its interaction with adiponutrin gene. J
Gastroenterol Hepatol. 28:873–879. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brondani LA, Assmann TS, de Souza BM,
Bouças AP, Canani LH and Crispim D: Meta-analysis reveals the
association of common variants in the uncoupling protein (UCP) 1–3
genes with body mass index variability. PLoS One. 9:e964112014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mexitalia M, Yamauchi T, Utari A, Sjarif
DR, Subagio HW, Soemantri A and Ishida T: The role of uncoupling
protein 2 and 3 genes polymorphism and energy expenditure in obese
Indonesian children. J Pediatr Endocrinol Metab. 26:441–447. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu YP, Liang L, Wang CL, Fu JF, Liu PN, Lv
LQ and Zhu YM: Association between UCP3 gene polymorphisms and
nonalcoholic fatty liver disease in Chinese children. World J
Gastroenterol. 19:5897–5903. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hashemi M, Hoseini H, Yaghmaei P,
Moazeni-Roodi A, Bahari A, Hashemzehi N and Shafieipour S:
Association of polymorphisms in glutamate-cysteine ligase catalytic
subunit and microsomal triglyceride transfer protein genes with
nonalcoholic fatty liver disease. DNA Cell Biol. 30:569–575. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tian Y, Li H, Wang S, Yan J, Chen Z, Li Z,
Feng H, Zhou H and Ouyang D: Association of L-FABP T94A and MTP
I128T polymorphisms with hyperlipidemia in Chinese subjects.
Lipids. 50:275–282. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Peng XE, Wu YL, Lu QQ, Hu ZJ and Lin X:
MTTP polymorphisms and susceptibility to non-alcoholic fatty liver
disease in a Han Chinese population. Liver Int. 34:118–128. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gambino R, Cassader M, Pagano G, Durazzo M
and Musso G: Polymorphism in microsomal triglyceride transfer
protein: A link between liver disease and atherogenic postprandial
lipid profile in NASH? Hepatology. 45:1097–1107. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wolff E, Vergnes MF, Defoort C, Planells
R, Portugal H, Nicolay A and Lairon D: Cholesterol absorption
status and fasting plasma cholesterol are modulated by the
microsomal triacylglycerol transfer protein −493 G/T polymorphism
and the usual diet in women. Genes Nutr. 6:71–79. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Siqueira ER, Oliveira CP, Correa-Giannella
ML, Stefano JT, Cavaleiro AM, Fortes MA, Muniz MT, Silva FS,
Pereira LM and Carrilho FJ: MTP −493G/T gene polymorphism is
associated with steatosis in hepatitis C-infected patients. Braz J
Med Biol Res. 45:72–77. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dongiovanni P, Rametta R, Fracanzani AL,
Benedan L, Borroni V, Maggioni P, Maggioni M, Fargion S and Valenti
L: Lack of association between peroxisome proliferator-activated
receptors alpha and gamma2 polymorphisms and progressive liver
damage in patients with non-alcoholic fatty liver disease: Α case
control study. BMC Gastroenterol. 10:1022010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Stienstra R, Saudale F, Duval C, Keshtkar
S, Groener JE, van Rooijen N, Staels B, Kersten S and Müller M:
Kupffer cells promote hepatic steatosis via
interleukin-1beta-dependent suppression of peroxisome
proliferator-activated receptor alpha activity. Hepatology.
51:511–522. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen S, Li Y, Li S and Yu C: A Val227Ala
substitution in the peroxisome proliferator activated receptor
alpha (PPAR alpha) gene associated with non-alcoholic fatty liver
disease and decreased waist circumference and waist-to-hip ratio. J
Gastroenterol Hepatol. 23:1415–1418. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Naito H, Yamanoshita O, Kamijima M, Katoh
T, Matsunaga T, Lee CH, Kim H, Aoyama T, Gonzalez FJ and Nakajima
T: Association of V227A PPARalpha polymorphism with altered serum
biochemistry and alcohol drinking in Japanese men. Pharmacogenet
Genomics. 16:569–577. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Domenici FA, Brochado MJ, Martinelli AL,
Zucoloto S, da Cunha SF and Vannucchi H: Peroxisome
proliferator-activated receptors alpha and gamma2 polymorphisms in
nonalcoholic fatty liver disease: A study in Brazilian patients.
Gene. 529:326–331. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sahebkar A: Does PPARγ2 gene Pro12Ala
polymorphism affect nonalcoholic fatty liver disease risk? Evidence
from a meta-analysis. DNA Cell Biol. 32:188–198. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yang Z, Wen J, Li Q, Tao X, Ye Z, He M,
Zhang W, Huang Y, Chen L, Ling C, et al: PPARG gene Pro12Ala
variant contributes to the development of non-alcoholic fatty liver
in middle-aged and older Chinese population. Mol Cell Endocrinol.
348:255–259. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cao CY, Li YY, Zhou YJ, Nie YQ and Wan YJ:
The C-681G polymorphism of the PPAR-γ gene is associated with
susceptibility to non-alcoholic fatty liver disease. Tohoku J Exp
Med. 227:253–262. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gawrieh S, Marion MC, Komorowski R,
Wallace J, Charlton M, Kissebah A, Langefeld CD and Olivier M:
Genetic variation in the peroxisome proliferator activated
receptor-gamma gene is associated with histologically advanced
NAFLD. Dig Dis Sci. 57:952–957. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bien CM and Espenshade PJ: Sterol
regulatory element binding proteins in fungi: Hypoxic transcription
factors linked to pathogenesis. Eukaryot Cell. 9:352–359. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Nagaya T, Tanaka N, Suzuki T, Sano K,
Horiuchi A, Komatsu M, Nakajima T, Nishizawa T, Joshita S, Umemura
T, et al: Down-regulation of SREBP-1c is associated with the
development of burned-out NASH. J Hepatol. 53:724–731. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang Y, Tong J, Chang B, Wang BF, Zhang D
and Wang BY: Relationship of SREBP-2 rs2228314 G>C polymorphism
with nonalcoholic fatty liver disease in a Han Chinese population.
Genet Test Mol Biomarkers. 18:653–657. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sun S, Wang M, Song H, Wu T, Wei H, He S,
Ding Z and Ji G: SCAP gene polymorphisms decrease the risk of
nonalcoholic fatty liver disease in females with metabolic
syndrome. J Genet. 92:565–570. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Younossi ZM, Gorreta F, Ong JP, Schlauch
K, Del Giacco L, Elariny H, van Meter A, Younoszai A, Goodman Z,
Baranova A, et al: Hepatic gene expression in patients with
obesity-related non-alcoholic steatohepatitis. Liver Int.
25:760–771. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Al-Serri A, Anstee QM, Valenti L, Nobili
V, Leathart JB, Dongiovanni P, Patch J, Fracanzani A, Fargion S,
Day CP, et al: The SOD2 C47T polymorphism influences NAFLD fibrosis
severity: Evidence from case-control and intra-familial allele
association studies. J Hepatol. 56:448–454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Krautbauer S, Eisinger K, Lupke M,
Wanninger J, Ruemmele P, Hader Y, Weiss TS and Buechler C:
Manganese superoxide dismutase is reduced in the liver of male but
not female humans and rodents with non-alcoholic fatty liver
disease. Exp Mol Pathol. 95:330–335. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Nahon P, Sutton A, Rufat P, Ziol M,
Akouche H, Laguillier C, Charnaux N, Ganne-Carrié N, Grando-Lemaire
V, N'Kontchou G, et al: Myeloperoxidase and superoxide dismutase 2
polymorphisms comodulate the risk of hepatocellular carcinoma and
death in alcoholic cirrhosis. Hepatology. 50:1484–1493. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kathirvel E, Chen P, Morgan K, French SW
and Morgan TR: Oxidative stress and regulation of anti-oxidant
enzymes in cytochrome P4502E1 transgenic mouse model of
non-alcoholic fatty liver. J Gastroenterol Hepatol. 25:1136–1143.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Liu W, Tian F, Dai L and Chai Y:
Cytochrome P450 2E1 gene polymorphism and alcohol drinking on the
risk of hepatocellular carcinoma: A meta-analysis. Mol Biol Rep.
41:7645–7650. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Khan AJ, Ruwali M, Choudhuri G, Mathur N,
Husain Q and Parmar D: Polymorphism in cytochrome P450 2E1 and
interaction with other genetic risk factors and susceptibility to
alcoholic liver cirrhosis. Mutat Res. 664:55–63. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Handa P, Morgan-Stevenson V, Maliken BD,
Nelson JE, Washington S, Westerman M, Yeh MM and Kowdley KV: Iron
overload results in hepatic oxidative stress, immune cell
activation, and hepatocellular ballooning injury, leading to
nonalcoholic steatohepatitis in genetically obese mice. Am J
Physiol Gastrointest Liver Physiol. 310:G117–G127. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Nelson JE, Brunt EM and Kowdley KV:
Nonalcoholic Steatohepatitis Clinical Research Network: Lower serum
hepcidin and greater parenchymal iron in nonalcoholic fatty liver
disease patients with C282Y HFE mutations. Hepatology.
56:1730–1740. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Lee SH, Jeong SH, Lee D, Lee JH, Hwang SH,
Cho YA, Park YS, Hwang JH, Kim JW, Kim N, et al: An epidemiologic
study on the incidence and significance of HFE mutations in a
Korean cohort with nonalcoholic fatty liver disease. J Clin
Gastroenterol. 44:e154–e161. 2010.PubMed/NCBI
|
|
61
|
Nelson JE, Yeh MM and Kowdley KV:
Relationship of C282Y HFE mutations, hepatic iron deposition and
histologic features in patients with nonalcoholic fatty liver
disease. Gastroenterology. 140:S938–S939. 2011.
|
|
62
|
Valenti L, Fracanzani AL, Bugianesi E,
Dongiovanni P, Galmozzi E, Vanni E, Canavesi E, Lattuada E, Roviaro
G, Marchesini G, et al: HFE genotype, parenchymal iron
accumulation, and liver fibrosis in patients with nonalcoholic
fatty liver disease. Gastroenterology. 138:905–912. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Rivera CA, Adegboyega P, van Rooijen N,
Tagalicud A, Allman M and Wallace M: Toll-like receptor-4 signaling
and Kupffer cells play pivotal roles in the pathogenesis of
non-alcoholic steatohepatitis. J Hepatol. 47:571–579. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Nagaya T, Tanaka N, Kimura T, Komatsu M
and Tanaka E: Enhanced expression of toll-like receptor 4 and MyD88
is associated with disease progression in human nonalcoholic fatty
liver disease. Gastroenterology. 140:S–978. 2011.
|
|
65
|
Thuy S, Ladurner R, Volynets V, Wagner S,
Strahl S, Königsrainer A, Maier KP, Bischoff SC and Bergheim I:
Nonalcoholic fatty liver disease in humans is associated with
increased plasma endotoxin and plasminogen activator inhibitor 1
concentrations and with fructose intake. J Nutr. 138:1452–1455.
2008.PubMed/NCBI
|
|
66
|
Peng D, Jiang F, Zhang R, Tang S, Chen M,
Yan J, Sun X, Luo Y, Hu C and Jia W: Association of Toll-like
Receptor 4 Gene polymorphisms with susceptibility to type 2
diabetes mellitus in the Chinese population. J Diabetes. 7:485–492.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Yin YW, Wang Q, Sun QQ, Hu AM and Liu HL:
Toll-like receptor 4 gene Asp299Gly and Thr399Ile polymorphisms in
type 2 diabetes mellitus: A meta-analysis of 15,059 subjects.
Diabetes Res Clin Pract. 107:338–347. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kiziltas S, Ata P, Colak Y, Mesçi B,
Senates E, Enc F, Ulasoglu C, Tuncer I and Oguz A: TLR4 gene
polymorphism in patients with nonalcoholic fatty liver disease in
comparison to healthy controls. Metab Syndr Relat Disord.
12:165–170. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Tache D, Bogdan F, Pisoschi C, Baniţă M,
Stănciulescu C, Fusaru AM and Comănescu V: Evidence for the
involvement of TGF-β1-CTGF axis in liver fibrogenesis secondary to
hepatic viral infection. Rom J Morphol Embryol. 52:409–412.
2011.PubMed/NCBI
|
|
70
|
Xiang TX, Cheng N, Li XN and Wu XP:
Association between transforming growth factor-β1 polymorphisms and
hepatocellular cancer risk: A meta-analysis. Hepatol Res.
42:583–590. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Mohy A and Fouad A: Role of transforming
growth factor-β1 in serum and − 509 C>T promoter gene
polymorphism in development of liver cirrhosis in Egyptian
patients. Meta Gene. 2:631–637. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Falleti E, Fabris C, Toniutto P, Fontanini
E, Cussigh A, Bitetto D, Fornasiere E, Avellini C, Minisini R and
Pirisi M: TGF-β1 genotypes in cirrhosis: Relationship with the
occurrence of liver cancer. Cytokine. 44:256–261. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Dai CY, Chuang WL, Lee LP, Pan WC, Huang
JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Hsieh MY, et al: Association
between transforming growth factor-beta 1 polymorphism and
virologic characteristics of chronic hepatitis C. Transl Res.
152:151–156. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Valenti L, Fracanzani AL, Dongiovanni P,
Santorelli G, Branchi A, Taioli E, Fiorelli G and Fargion S: Tumor
necrosis factor alpha promoter polymorphisms and insulin resistance
in nonalcoholic fatty liver disease. Gastroenterology. 122:274–280.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Tokushige K, Takakura M,
Tsuchiya-Matsushita N, Taniai M, Hashimoto E and Shiratori K:
Influence of TNF gene polymorphisms in Japanese patients with NASH
and simple steatosis. J Hepatol. 46:1104–1110. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Wang JK, Feng ZW, Li YC, Li QY and Tao XY:
Association of tumor necrosis factor-α gene promoter polymorphism
at sites −308 and −238 with non-alcoholic fatty liver disease: A
meta-analysis. J Gastroenterol Hepatol. 27:670–676. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Wei Y, Liu F, Li B, Chen X, Ma Y, Yan L,
Wen T, Xu M, Wang W and Yang J: Polymorphisms of tumor necrosis
factor-alpha and hepatocellular carcinoma risk: A HuGE systematic
review and meta-analysis. Dig Dis Sci. 56:2227–2236. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Marginean O, Banescu C, Duicu C, Marginean
M Oana and Marginean C: The role of interleukin-6 gene 572G/C
polymorphism in child obesity. Clin Nutr. 33:S1172014. View Article : Google Scholar
|
|
79
|
Giannitrapani L, Soresi M, Balasus D,
Licata A and Montalto G: Genetic association of interleukin-6
polymorphism (−174 G/C) with chronic liver diseases and
hepatocellular carcinoma. World J Gastroenterol. 19:2449–2455.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Deng Y, Li M, Wang J, Xie L, Li T, He Y,
Lu Q, Li R, Tan A, Qin X, et al: Susceptibility to hepatocellular
carcinoma in the Chinese population-associations with interleukin-6
receptor polymorphism. Tumour Biol. 35:6383–6388. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Bedogni G, Miglioli L, Masutti F,
Tiribelli C, Marchesini G and Bellentani S: Prevalence of and risk
factors for nonalcoholic fatty liver disease: The Dionysos
nutrition and liver study. Hepatology. 42:44–52. 2005. View Article : Google Scholar : PubMed/NCBI
|
